A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma

Nikoletta Lendvai, Patrick Hilden, Sean Devlin, Heather Landau, Hani Hassoun, Alexander M. Lesokhin, Ioanna Tsakos, Kaitlyn Redling, Guenther Koehne, David J. Chung, Wendy L. Schaffer, Sergio A. Giralt

Research output: Contribution to journalArticlepeer-review

Original languageAmerican English
JournalBlood
Volume124
DOIs
StatePublished - Aug 7 2014

Disciplines

  • Medicine and Health Sciences
  • Oncology
  • Immunology and Infectious Disease

Cite this